■研究表明,肌肉减少症和内脏肥胖是中老年人慢性疾病的重要危险因素。然而,肌少症之间的关系,心脏代谢指数(CMI),一种衡量内脏肥胖的新方法,和心脏代谢多症(CMM)仍不清楚。在这项研究中,我们对中国健康与退休纵向研究(CHARLS)的数据进行了分析,以调查中老年人群肌肉减少症和CMI与CMM之间的关系.
■该研究包括4,959名45岁及以上的参与者。使用亚洲肌肉减少症工作组2019的标准定义肌肉减少症。CMM被定义为具有以下两种或多种情况:医生诊断的心脏病,糖尿病,中风,和/或高血压。使用下式计算CMI:CMI=(TG/HDL-C)XWHtR。探讨CMI与肌少症和CMM的关系,使用cox比例风险回归模型。
■所有参与者的平均年龄为57岁,其中47.1%是男性。在8年的随访中,1,362个人开发了CMM。无肌肉减少症或高CMI组CMM发病率为8.7/1000人年,17.37/1,000人年在那些具有高CMI,14.22/1000人年在肌肉减少症组,和22.34/1000人年在这两个条件的组中。在调整协变量后,同时患有肌肉减少症和高CMI的组发生CMM(HR2.48,95%CI1.12-5.51)和心脏病(HR2.04,95%CI1.05-3.98)的风险显著增加.在65岁以上的人中,发现少肌症与CMM风险增加相关[HR(95%CI:4.83(1.22,19.06)]。当与高CMI合并时,CMM的风险进一步增加至7.31倍(95%CI:1.72,31.15)。
■少肌症和高CMI的组合与发生CMM的风险增加有关。早期识别和干预肌少症和CMI不仅可以制定有针对性的治疗策略,而且还为降低CMM的发病率和死亡率提供了潜在的机会。
UNASSIGNED: Research has demonstrated that sarcopenia and visceral obesity are significant risk factors for chronic disease in middle-aged and older adults. However, the relationship between sarcopenia, the cardiac metabolic index (CMI), a novel measure of visceral obesity, and cardiometabolic multimorbidity (CMM) remains unclear. In this study, data from the China Longitudinal Study of Health and Retirement (
CHARLS) were analyzed to investigate the association between sarcopenia and CMI with CMM in the middle-aged and older adult population.
UNASSIGNED: The study included 4,959 participants aged 45 and over. Sarcopenia was defined using the criteria of the Asian Sarcopenia Working Group 2019. CMM is defined as having two or more of the following conditions: physician-diagnosed heart disease, diabetes, stroke, and/or hypertension. CMI was calculated using the formula: CMI = (TG/HDL-C) × WHtR. To explore the association between CMI and sarcopenia and CMM, cox proportional risk regression models were used.
UNASSIGNED: The median age of all participants was 57 years, with 47.1% being male. Over the 8-year follow-up, 1,362 individuals developed CMM. The incidence of CMM was 8.7/1,000 person-years in the group without sarcopenia or high CMI, 17.37/1,000 person-years in those with high CMI, 14.22/1,000 person-years in the sarcopenia group, and 22.34/1,000 person-years in the group with both conditions. After adjusting for covariates, the group with both sarcopenia and high CMI had a significantly increased risk of CMM (HR 2.48, 95% CI 1.12-5.51) and heart disease (HR 2.04, 95% CI 1.05-3.98). Among those over 65 years, sarcopenia was discovered to be associated with an increased risk of CMM [HR (95% CI: 4.83 (1.22, 19.06)]. The risk of CMM was further increased to 7.31-fold (95% CI:1.72, 31.15) when combined with high CMI.
UNASSIGNED: The combination of sarcopenia and high CMI is associated with an increased risk of developing CMM. Early identification and intervention of sarcopenia and CMI not only enable the development of targeted therapeutic strategies but also provide potential opportunities to reduce the morbidity and mortality of CMM.